165 related articles for article (PubMed ID: 27709126)
21. Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection.
Wizel B; Garg N; Tarleton RL
Infect Immun; 1998 Nov; 66(11):5073-81. PubMed ID: 9784506
[TBL] [Abstract][Full Text] [Related]
22. Recombinant yellow fever viruses elicit CD8+ T cell responses and protective immunity against Trypanosoma cruzi.
Nogueira RT; Nogueira AR; Pereira MC; Rodrigues MM; Neves PC; Galler R; Bonaldo MC
PLoS One; 2013; 8(3):e59347. PubMed ID: 23527169
[TBL] [Abstract][Full Text] [Related]
23. Genetic immunization based on the ubiquitin-fusion degradation pathway against Trypanosoma cruzi.
Chou B; Hiromatsu K; Hisaeda H; Duan X; Imai T; Murata S; Tanaka K; Himeno K
Biochem Biophys Res Commun; 2010 Feb; 392(3):277-82. PubMed ID: 20059980
[TBL] [Abstract][Full Text] [Related]
24. ASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of Chagas' disease.
Castro JT; Brito R; Hojo-Souza NS; Azevedo B; Salazar N; Ferreira CP; Junqueira C; Fernandes AP; Vasconcellos R; Cardoso JM; Aguiar-Soares RDO; Vieira PMA; Carneiro CM; Valiate B; Toledo C; Salazar AM; Caballero O; Lannes-Vieira J; Teixeira SR; Reis AB; Gazzinelli RT
NPJ Vaccines; 2023 May; 8(1):81. PubMed ID: 37258518
[TBL] [Abstract][Full Text] [Related]
25. CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2.
Araújo AF; de Alencar BC; Vasconcelos JR; Hiyane MI; Marinho CR; Penido ML; Boscardin SB; Hoft DF; Gazzinelli RT; Rodrigues MM
Infect Immun; 2005 Sep; 73(9):6017-25. PubMed ID: 16113322
[TBL] [Abstract][Full Text] [Related]
26. Signal transduction in human macrophages by gp83 ligand of Trypanosoma cruzi: trypomastigote gp83 ligand up-regulates trypanosome entry through protein kinase C activation.
Villalta F; Zhang Y; Bibb KE; Pratap S; Burns JM; Lima MF
Mol Cell Biol Res Commun; 1999 Jul; 2(1):64-70. PubMed ID: 10527894
[TBL] [Abstract][Full Text] [Related]
27. Generation of neutralizing monoclonal antibodies against a conformational epitope of human adenovirus type 7 (HAdv-7) incorporated in capsid encoded in a HAdv-3-based vector.
Liu M; Tian X; Li X; Zhou Z; Li C; Zhou R
PLoS One; 2014; 9(7):e103058. PubMed ID: 25054273
[TBL] [Abstract][Full Text] [Related]
28. Co-administration of a plasmid DNA encoding IL-15 improves long-term protection of a genetic vaccine against Trypanosoma cruzi.
Eickhoff CS; Vasconcelos JR; Sullivan NL; Blazevic A; Bruna-Romero O; Rodrigues MM; Hoft DF
PLoS Negl Trop Dis; 2011 Mar; 5(3):e983. PubMed ID: 21408124
[TBL] [Abstract][Full Text] [Related]
29. A Recombinant Chimeric Ad5/3 Vector Expressing a Multistage Plasmodium Antigen Induces Protective Immunity in Mice Using Heterologous Prime-Boost Immunization Regimens.
Cabrera-Mora M; Fonseca JA; Singh B; Zhao C; Makarova N; Dmitriev I; Curiel DT; Blackwell J; Moreno A
J Immunol; 2016 Oct; 197(7):2748-61. PubMed ID: 27574299
[TBL] [Abstract][Full Text] [Related]
30. Human infection with Trypanosoma cruzi induces parasite antigen-specific cytotoxic T lymphocyte responses.
Wizel B; Palmieri M; Mendoza C; Arana B; Sidney J; Sette A; Tarleton R
J Clin Invest; 1998 Sep; 102(5):1062-71. PubMed ID: 9727076
[TBL] [Abstract][Full Text] [Related]
31. Comparative Evaluation of the Vaccine Efficacies of Three Adenovirus-Based Vector Types in the Friend Retrovirus Infection Model.
Hrycak CP; Windmann S; Bayer W
J Virol; 2019 Nov; 93(21):. PubMed ID: 31375593
[TBL] [Abstract][Full Text] [Related]
32. Immunization With Lipopolysaccharide-Activated Dendritic Cells Generates a Specific CD8
Biscari L; Kaufman CD; Farré C; Huhn V; Pacini MF; Balbi CB; Gómez KA; Pérez AR; Alloatti A
Front Cell Infect Microbiol; 2022; 12():897133. PubMed ID: 35903201
[TBL] [Abstract][Full Text] [Related]
33. A Two-Component DNA-Prime/Protein-Boost Vaccination Strategy for Eliciting Long-Term, Protective T Cell Immunity against Trypanosoma cruzi.
Gupta S; Garg NJ
PLoS Pathog; 2015 May; 11(5):e1004828. PubMed ID: 25951312
[TBL] [Abstract][Full Text] [Related]
34. Pseudopackaging of adenovirus type 5 genomes into capsids containing the hexon proteins of adenovirus serotypes B, D, or E.
Ostapchuk P; Hearing P
J Virol; 2001 Jan; 75(1):45-51. PubMed ID: 11119572
[TBL] [Abstract][Full Text] [Related]
35. Adenovirus-based vaccine with epitopes incorporated in novel fiber sites to induce protective immunity against Pseudomonas aeruginosa.
Sharma A; Krause A; Xu Y; Sung B; Wu W; Worgall S
PLoS One; 2013; 8(2):e56996. PubMed ID: 23437292
[TBL] [Abstract][Full Text] [Related]
36. Therapeutical effects of vaccine from Trypanosoma cruzi amastigote surface protein 2 by simultaneous inoculation with live parasites.
Ribeiro FAP; Pontes C; Machado AMV; Bruna-Romero O; Quintana HT; De Oliveira F; De Vasconcelos JRC; Ribeiro DA
J Cell Biochem; 2019 Mar; 120(3):3373-3383. PubMed ID: 30246366
[TBL] [Abstract][Full Text] [Related]
37. Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination.
Cheng C; Wang L; Gall JG; Nason M; Schwartz RM; McElrath MJ; DeRosa SC; Hural J; Corey L; Buchbinder SP; Nabel GJ
PLoS One; 2012; 7(4):e33969. PubMed ID: 22496775
[TBL] [Abstract][Full Text] [Related]
38. Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase.
Machado AV; Cardoso JE; Claser C; Rodrigues MM; Gazzinelli RT; Bruna-Romero O
Hum Gene Ther; 2006 Sep; 17(9):898-908. PubMed ID: 16972758
[TBL] [Abstract][Full Text] [Related]
39. Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" strategy.
Gu L; Krendelchtchikova V; Krendelchtchikov A; Farrow AL; Derdeyn CA; Matthews QL
Virology; 2016 Jan; 487():75-84. PubMed ID: 26499044
[TBL] [Abstract][Full Text] [Related]
40. Examination of antigenic proteins of Trypanosoma cruzi to fabricate an epitope-based subunit vaccine by exploiting epitope mapping mechanism.
Khatoon N; Ojha R; Mishra A; Prajapati VK
Vaccine; 2018 Oct; 36(42):6290-6300. PubMed ID: 30217522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
